- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03472495
Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial (OVID RAF)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Atrial fibrillation (AF), a supraventricular tachyarrhythmia, is the primary diagnosis for over 467,000 hospitalizations each year. Historically, there have been two approaches to managing AF in the emergency department (ED): rate control and rhythm control.
The AFFIRM trial compared rate and rhythm control in 4,060 patients. It found no difference in mortality with the rate control approach and less hospitalizations. As a result, both rhythm and rate control are options in stable patients with an AF duration of < 48 hours. After 48 hours, rate control is preferred because of the increased risk of ischemic stroke. The subsequent RACE II trial, established that lenient heart rate control (HR <110 beats/min) was as effective as strict control (HR <80 beats/min) in preventing cardiovascular events and required less outpatient visits to achieve the goal HR. As a result of both the AFFIRM and RACE II trials, a rate control approach with a goal HR of <80-110 beats/min is the management plan for a majority of patients who present to the ED in AF. According to the American Heart Association 2014 guidelines, the initial acute, emergent management of atrial fibrillation and flutter (AFF) are similar and there are a number of medications used for rate control including beta blockers and non-dihydropyridine calcium channel blockers.
Diltiazem, a non-dihydropyridine calcium channel blocker, is often the medication of choice in the management of AFF due to its ability to be given as an intravenous (IV) push, continuous infusion, and oral (PO) immediate release or extended release tablet. In the ED, a loading dose of IV diltiazem 0.25 mg/kg is usually administered to obtain a heart rate of < 110 beats/min or a decrease of at least 20% in the ventricular rate. If this does not work then a second bolus of 0.35mg/kg is administered. Once rate control of <110 beats/min or a 20% decrease in ventricular rate is obtained physicians typically chose between oral immediate release diltiazem tablet or IV continuous infusion diltiazem to maintain heart rate control. Both options allow for dose changes in the short term. The oral immediate release diltiazem tablet has a fast onset of action of 30-60 minutes and is dosed every 6 hours. Intravenous continuous infusion diltiazem has a variable onset of action with a titration frequency of every 15-30 minutes. The use of oral diltiazem allows for possible placement on a monitored general floor bed, whereas an intravenous drip requires placement to step down or intensive level of care. This impacts bed status and length of stay in the emergency department. Both oral and intravenous diltiazem are used clinically; however, no prospective studies exist comparing the two strategies. Retrospective data suggests that both forms are equal in their ability to control heart rate.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- >/= 18 years old
- Atrial fibrillation or flutter on electrocardiogram
- Heart rate >110 beats/min
- Systolic blood pressure >/= 90 mmHg
Exclusion Criteria:
- Limited English proficiency (LEP)
- Pregnant
- Prisoners
- Wolff Parkinson White syndrome
- Administration of electrical or chemical cardioversion before screening
- Administration of other antiarrhythmics for acute heart rate control (excluding adenosine)
- History of allergy or idiosyncratic reaction to diltiazem
- Unable to take oral medications
- Heart rate <60 beats/min
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Oral Immediate Release Diltiazem
Diltiazem immediate release 60mg orally once (Diltiazem oral product)
|
Diltiazem Immediate Release 60 MG PO Q6H (30 MG PO Q6H if patient is <60 kg)
|
Active Comparator: Continuous Infusion IV Diltiazem
Diltiazem 2.5-5 mg/hour intravenous Titrate by 1.25 mg every 15-60 minutes.
Maximum titration dose 15 mg/hour.
Titration Goal of HR <110 (Diltiazem Injectable Product)
|
Diltiazem Continuous Infusion Titrated
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Heart Rate Control
Time Frame: 2 hrs
|
Number of participant achieving heart rate control (defined as: HR <110 beats/min or conversion to sinus rhythm) at 2 hours after medication administration between oral immediate release and intravenous continuous infusion diltiazem
|
2 hrs
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Event Rate
Time Frame: 4 hrs
|
Number of participants with heart rate or blood pressure adverse events: Heart rate < 60 beats/min, or systolic blood pressure <90 mmHg requiring intervention (intravenous fluid bolus, vasopressors, medication discontinuation)
|
4 hrs
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participant Specific Variables Associated With Heart Rate Control in Each Treatment Arm
Time Frame: 4 hrs
|
These variables include: Age, sex, race, weight, history of atrial fibrillation or flutter, history of hypertension, history of congestive heart failure, prior medication therapy, mean initial HR, duration of atrial fibrillation or flutter episode (<48 hrs or >48 hrs), mean initial diltiazem dose (mg/kg)
|
4 hrs
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tammy T Nguyen, PharmD, BCPS, Virginia Commonwealth University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Arrhythmias, Cardiac
- Atrial Fibrillation
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Diltiazem
Other Study ID Numbers
- HM20009559
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation and Flutter
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Angelo BivianoCompleted
-
Kaiser PermanenteActive, not recruitingAtrial Fibrillation and FlutterUnited States
-
Oman Medical Speciality BoardNot yet recruitingAtrial Fibrillation With Rapid Ventricular Response | Atrial Flutter With Rapid Ventricular ResponseOman
-
University of PennsylvaniaWithdrawnTypical Atrial Flutter | Risk Factors With Future Development of Atrial FlutterUnited States
-
Boston Scientific CorporationWithdrawnAtrial Tachycardia (Including Atrial Flutter) Post Atrial Fibrillation Ablation or Cardiac SurgeryChina
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
-
Johannes Gutenberg University MainzBoehringer Ingelheim; Atrial Fibrillation NetworkTerminatedAtrial Fibrillation or Atrial Flutter | Thrombosis of Left Atrial AppendageGermany
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
Clinical Trials on Diltiazem Oral Product
-
Instituto do Cancer do Estado de São PauloRecruitingHepatocellular Carcinoma | Liver CancerBrazil
-
UAS Labs LLCCompleted
-
University Hospital, BordeauxCompleted
-
St George's, University of LondonRecruitingChronic Kidney Diseases | Heart Failure With Reduced Ejection Fraction | Hyperkalemia | ACE Inhibitor Induced Hyperkalaemia | Mineralocorticoid Resistant HyperkalemiaUnited Kingdom
-
Xenon Pharmaceuticals Inc.CompletedHealthy VolunteersUnited Kingdom
-
Brigham and Women's HospitalUnknownChronic Kidney Diseases | HyperkalemiaUnited States
-
Peking Union Medical College HospitalUnknown
-
Duke UniversityVifor PharmaCompletedEnd Stage Renal Disease | HyperkalemiaUnited States
-
National Cheng Kung UniversityNational Cheng-Kung University Hospital; Ministry of Science and Technology...Recruiting
-
Ventrus Biosciences, IncUnknownAdult Subjects With Anal Fissures.United States